1. AnonInstitute for quality and efficiency in health care. Validity of surrogate endpoints in oncology: executive summary. Accessed August, 2021. 〈https://www.iqwig.de/en/projects/a10–05.html; https://www.iqwig.de/download/a10–05_rapid_report_version_1–1_surrogatendpunkte_in_der_onkologie.pdf〉.
2. The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL;Assouline;Blood Adv.,2020
3. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups;Batlevi;Blood Cancer J.,2020
4. Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines;Brody,2016
5. Bujkiewicz SAF, Papanikos T., Riley RD, Abrams KR,. NICE DSU Technical Support Document 20: multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints. 〈https://nicedsu.sites.sheffield.ac.uk/tsds〉.